Raylene sells GEVA 72.31: Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 10% After Naming Cancer-Speci ...
Dr. Mark Goldberg is executive vice president for medical and regulatory strategy at Synageva BioPharma ( GEVA) in addition to appointments at Brigham and Women's Hospital and the Dana Farber Cancer Institute. He is also an associate clinical professor of ... ...
45 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home